Gibbs Wealth Management boosted its stake in Repligen Corporation (NASDAQ:RGEN – Free Report) by 99.9% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,713 shares of the biotechnology company’s stock after purchasing an additional 5,353 shares during the quarter. Gibbs Wealth Management’s holdings in Repligen were worth $1,262,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of the company. Measured Wealth Private Client Group LLC bought a new position in Repligen in the 3rd quarter valued at about $29,000. Bayforest Capital Ltd acquired a new position in shares of Repligen in the 4th quarter valued at approximately $32,000. Rachor Investment Advisory Services LLC bought a new stake in shares of Repligen during the 4th quarter worth approximately $33,000. Los Angeles Capital Management LLC bought a new stake in shares of Repligen during the 4th quarter worth approximately $36,000. Finally, Farther Finance Advisors LLC boosted its position in shares of Repligen by 61.8% during the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 128 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.
Repligen Price Performance
Shares of RGEN opened at $137.60 on Friday. Repligen Corporation has a 12-month low of $100.99 and a 12-month high of $175.77. The business has a 50-day simple moving average of $131.09 and a two-hundred day simple moving average of $132.60. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26. The stock has a market cap of $7.76 billion, a PE ratio of 152.89, a PEG ratio of 2.70 and a beta of 1.06.
Insider Buying and Selling
In other Repligen news, CFO Jason K. Garland sold 733 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the sale, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at $2,807,055. The trade was a 3.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.60% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
RGEN has been the subject of several research analyst reports. Weiss Ratings upgraded shares of Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, July 14th. HSBC cut their target price on Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd. Citigroup upgraded Repligen to a “buy” rating in a research note on Tuesday, July 7th. Jefferies Financial Group reissued a “hold” rating and set a $142.00 price target on shares of Repligen in a report on Tuesday, May 5th. Finally, JPMorgan Chase & Co. dropped their price objective on Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $165.36.
Check Out Our Latest Report on Repligen
Key Stories Impacting Repligen
Here are the key news stories impacting Repligen this week:
- Positive Sentiment: The deal should strengthen Repligen’s position in cell therapy by adding BioLife’s biopreservation media and cell processing tools, expanding its addressable market and customer offering. Article Title
- Positive Sentiment: Management said the transaction should be accretive to adjusted EPS by at least $0.05 in year one and $0.25 in year two, with at least $20 million in synergies in year one and $30 million in year two. Article Title
- Positive Sentiment: Preliminary Q2 results were also supportive, with Repligen expecting about 12% reported revenue growth and 13% organic growth, suggesting continued underlying business momentum. Article Title
- Neutral Sentiment: The merger is not expected to close until Q4 2026 and still needs regulatory and shareholder approvals, leaving some timing uncertainty. Article Title
- Negative Sentiment: The market may be reacting to dilution and integration concerns because the purchase is being funded with both cash and Repligen stock, while the acquired business adds execution risk if expected synergies do not materialize. Article Title
Repligen Profile
Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.
The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.
Featured Articles
- Five stocks we like better than Repligen
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN – Free Report).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
